Navigation Links
Ambien and the Other Insomnia Drugs

Ambien is produced and marked by Sanofi-Aventis. It is one of the leading insomnia drug companies. But at present it is in great trouble as its drug is going to go// off-patent this October. There's a range of insomnia drugs on the market, and more are on the way. This is a great relief for some of the people who depend on Ambien for a good night’s sleep.

Good news has been in short supply for the French pharmaceutical company of late. A string of media reports recently highlighted the links between Ambien and sleepwalking, binge eating, and even dangerous nighttime driving.

The side effects though already known and mentioned on the product label are attracting increased attention. It’s just a matter of time before cheaper generic versions of insomnia drugs hit the market. Sanofi-Aventis is hoping to withstand some of the threat. Ambien has the lion's share of the $2 billion prescription insomnia drug market.

Sepracor's Lunesta, available since last April, accounts for about 10%. The drug raked in $329.2 million in its first few months. According to National Sleep Foundation (NSF) it was found that 6 out of l0 people approximately about 126 million people experience at least one symptom of insomnia a few nights a week.

But at present Ian Anderson, an analyst at Cowen & Co, says that only 16% of the patient population is being treated with drug therapy. He also predicts that the market would grow up to 30% this year. Indiplon, created by Pfizer and Neurocrine Biosciences is expected to hit the markets this autumn but their approval by the Food & Drug Administration is pending.

The drug will come in two forms. The short-acting version is meant to help treat jetlag and other short-term sleep needs, such as waking up in the middle of the night. Indiplon's relatively short half-life reduces the hangover-like effect, particularly for people who use the drug in the middle of the night.

But Ambien and Lunesta b oth have longer half-lives, so they are typically not used as middle-of-the-night solutions. But the drug companies have recently asked each other not to begin TV and print advertising of new prescription medicine until physicians have had at least six months to learn more about them.

This is because they feel that ads would generate more immediate interest in a drug. The waiting period is aimed at fostering dialogue between patients and their physicians. It could mean patients will make more informed choices about prescription drugs.


'"/>




Related medicine news :

1. Aromatherapy: Ambient odors of orange and lavender reduce anxiety
2. Ambien Plus Alcohol Has A Bad Influence on the Drivers
3. Tune Your Brain to Hear Another in a Noisy Ambience
4. FDA Approves First Generic Versions of Ambien for Insomnia
5. Twins Less Prone to Suicide Than Others
6. Sleep Disorders Could Indicate Other Medical Problems
7. Features Of The Brain Affect Asthma And Other Stress Related Disorders
8. Smokers Avoid Dental Care More Than Others
9. Brain Patterns In Amusia May Be Related To Other Disorders
10. Genetic Eye Disorder Can Have Other Implications
11. Some See A Hopeless End, While Others See An Endless Hope
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... 2017 , ... With millions of Americans and people worldwide ... all are aware of our options and are empowered with strength and information ... of its newest edition of "Vision and Hearing" in USA Today, that will ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have the ability ... total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, individual glass ... , With ProGlass Prism users are given the tools and effects to generate ...
(Date:2/24/2017)... ... 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) announces ... See” body image mannequin art competition. Selected from 15 submissions from around the nation, ... at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. , ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, ... thought leadership , media relations, social media, content marketing and SEO, is ... powered through Act-On, an intuitive marketing automation platform. , Rosica will now offer ...
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... an official 2017 partnership with The Jensie Gran Fondo of Marin. For the ... UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to provide ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... ITL Limited, ( ASX: ITD ), an innovative diversified ... year ended 31 December 2016 compared with the previous corresponding period. ... viewed here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: ... 2015: $15.7m; up 11%) Profit before tax of ...
(Date:2/23/2017)... Research and Markets has announced the addition ... 2016" report to their offering. ... The latest research Oesophageal Cancer Drugs Price ... in the global Oesophageal Cancer market. The research answers ... key drugs marketed for Oesophageal Cancer and their clinical attributes? How ...
(Date:2/23/2017)... COTTAGE, New York , February 23, 2017 /PRNewswire/ ... health implications arising from increasing caseload for varicose veins ... recorded across the globe are prompting the adoption of ... latest study on global endovenous laser therapy ... attention towards aftereffects of lifestyle choices and consequences of ...
Breaking Medicine Technology: